<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>PHENAZO - phenazopyridine hydrochloride tablet </strong><br>Contract Pharmacal Corp<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>PHENAZOPYRIDINE<br>
HYDROCHLORIDE<br>
TABLETS<br>
95 mg</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1><span class="Bold">DESCRIPTION
</span></h1>
<p class="First">Phenazopyridine Hydrochloride is light or dark red to dark violet, odorless, slightly bitter, crystalline powder. It has a specific local <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> in the urinary tract, promptly relieving burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. It has the following structural formula.</p>
<div class="Figure"><img alt="d6192ba4-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=78506c63-8061-499c-a57e-bdd88f805591&amp;name=d6192ba4-figure-01.jpg"></div>
<p>Phenazopyridine HCl tablets contain the following</p>
</div>
<div class="Section" data-sectionCode="55106-9">
<a name="section-2"></a><p></p>
<h1><span class="Bold">ACTIVE INGREDIENT(in each tablet)
</span></h1>
<p class="First">Phenazopyridine HCl 95 mg</p>
</div>
<div class="Section" data-sectionCode="51727-6">
<a name="section-3"></a><p></p>
<h1><span class="Bold">INACTIVE INGREDIENT
</span></h1>
<p class="First">Lactose, Magnesium Silicate, Magnesium Stearate, Microcrystalline Cellulose, Pharmaceutical Glaze and Sodium Starch Glycolate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY
</span></h1>
<p class="First">Phenazopyridine HCl is excreted in the urine where it exerts a topical <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> on the mucosa of the urinary tract. This action helps to relieve <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, burning, urgency and frequency. The precise mechanism of action is not known.</p>
<p>The pharmacokinetic properties of Phenazopyridine HCl have not been determined.  Phenazopyridine HCl is rapidly excreted by the kidneys, with as much as 65% of an oral dose being excreted unchanged in the urine.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE
</span></h1>
<p class="First">Phenazopyridine HCl is indicated for the symptomatic relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, burning, urgency,</p>
<p>frequency, and other <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomforts</span> arising from irritation of the lower urinary tract mucosa caused by <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine HCl for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. Because it provides only symptomatic relief, prompt appropriate treatment of the cause of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> must be instituted and Phenazopyridine HCl should be discontinued when symptoms are controlled.</p>
<p>The analgesic action may reduce or eliminate the need for systemic analgesics or narcotics. It is, however, compatible with antibacterial therapy and can help to relieve <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> during the interval before antibacterial therapy controls the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Treatment of a <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> with Phenazopyridine HCl should not exceed 2 days because there is a lack of evidence that the combined administration of Phenazopyridine HCl and an antibacterial provides greater benefit than administration of the antibacterial alone after two days. (See <a href="#bdd1f932-d483-420b-8467-afb5ee522f04">DOSAGE AND ADMINISTRATION</a> section.)</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS
</span></h1>
<p class="First">Phenazopyridine HCl should not be used in patients who have previously exhibited <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to it. The use of Phenazopyridine HCl is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS
</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and occasional <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbance</span>. An anaphylactoid-like reaction has been described. <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, renal and hepatic toxicity have been described, usually at <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> levels (see <a href="#be7dfb82-4f84-4a04-8684-4f410bdc5ef0">Overdosage</a> Section).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1><span class="Bold">PRECAUTIONS
</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2><span class="Bold Italics">General
</span></h2>
<p class="First">A yellowish tinge of the skin or sclera may indicate accumulation due to impaired renal excretion and the need to discontinue therapy. The decline in renal function associated with advanced age should be kept in mind.</p>
<p>NOTE: Patients should be informed that Phenazopyridine HCl produces a reddish-orange discoloration of the urine and may stain fabric. Staining of contact lenses has been reported.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-8.2"></a><p></p>
<h2><span class="Bold Italics">Laboratory Test Interaction
</span></h2>
<p class="First">Due to its property as an azo dye, Phenazopyridine HCl may interfere with urinalysis based on spectrometry or color reactions.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.3"></a><p></p>
<h2><span class="Bold Italics">Carcinogenesis, Mutagenesis, Impairment of Fertility
</span></h2>
<p class="First">Long-term administration of Phenazopyridine HCl has induced neoplasia in rats (large intestine) and mice (liver); although no association between Phenazopyridine HCl and human neoplasia has been reported, adequate epidemiological studies along these lines have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.4"></a><p></p>
<h2><span class="Bold Italics">Pregnancy Category B
</span></h2>
<p class="First">Reproduction studies have been performed in rats at doses up to 50 mg/kg/day and have revealed no evidence of impaired fertility or harm to the fetus due to Phenazopyridine HCl. There are however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.5"></a><p></p>
<h2><span class="Bold Italics">Nursing Mothers
</span></h2>
<p class="First">No information is available on the appearance of Phenazopyridine HCl, or its metabolites in human milk.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="bdd1f932-d483-420b-8467-afb5ee522f04"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION
</span></h1>
<p class="First">95 mg. Tablets: Average adult dosage is two tablets 3 times a day after meals.</p>
<p>When used concomitantly with an antibacterial agent for the treatment of a <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, the administration of Phenazopyridine HCl should not exceed 2 days.</p>
</div>
<div class="Section" data-sectionCode="55105-1">
<a name="section-10"></a><p></p>
<h1><span class="Bold">PURPOSE
</span></h1>
<p class="First">Urinary Analgesic</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="be7dfb82-4f84-4a04-8684-4f410bdc5ef0"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">OVERDOSAGE
</span></h1>
<p class="First">Exceeding the recommended dose in patients with good renal function or administering the usual dose to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (common in elderly patients) may lead to increased serum levels and toxic reactions. <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> generally follows a massive, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span>. Methylene blue, 1 to 2 mg/kg/body weight intravenously or ascorbic acid 100 to 200 mg. given orally should cause prompt reduction of the <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> and disappearance of the <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> which is an aid in diagnosis. Oxidative Heinz Body <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic Anemia</span> may also occur, and "bite cells" (degmacytes) may be present in a chronic overdosage situation. Red blood cell G-6-PD deficiency may predispose to <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>. Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and occasional failure, usually due to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, may also occur.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-12"></a><p></p>
<h1><span class="Bold">WARNINGS
</span></h1>
<p class="First"><span class="Bold">Ask a doctor before use if you have</span></p>
<ul class="Disc">
<li>kidney disease</li>
<li>allergies to foods, preservatives or dyes</li>
<li>had a hypersensitive reaction to Phenazopyridine</li>
</ul>
<p>Caution: Do not use this product if you have Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency unless approved by your physician.</p>
<p><span class="Bold">When using this product </span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach upset</span> may occur, taking this product with or after meals may reducer <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach upset</span></li>
<li>your urine will become reddish-orange in color. This is not harmful, but care should be taken to avoid staining clothing or other items.</li>
</ul>
<p><span class="Bold">Stop use and ask a doctor if </span></p>
<ul class="Disc">
<li>your symptoms last more than two days</li>
<li>you suspect you are having an adverse reaction to the medication.</li>
</ul>
<p><span class="Bold">If pregnant or breast-feeding,</span> ask a health professional before use.</p>
</div>
<div class="Section" data-sectionCode="50565-1">
<a name="section-13"></a><p></p>
<h1><span class="Bold">Keep out of reach of children
</span></h1>
<p class="First">In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, get medical help or a Poison Control Center right away.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED
</span></h1>
<p class="First">Phenazopyridine Hydrochloride tablets are supplied in bottles of 24 and 30 tablets or strips of 30’s.</p>
<p>Store at room temperature, USP.</p>
<p><span class="Bold">Manufactured by:</span></p>
<p>Contract Pharmacal Corp.</p>
<p>135 Adams Ave.</p>
<p>Hauppauge, NY 11788 U.S.A.</p>
<p>www.cpc.com</p>
<p>Rev. 12/08</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</span></h1>
<div class="Figure"><img alt="d6192ba4-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=78506c63-8061-499c-a57e-bdd88f805591&amp;name=d6192ba4-figure-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PHENAZO 		
					</strong><br><span class="contentTableReg">phenozapyridine hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN OTC DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10267-0064</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PHENAZOPYRIDINE HYDROCHLORIDE</strong> (PHENAZOPYRIDINE) </td>
<td class="formItem">PHENAZOPYRIDINE HYDROCHLORIDE</td>
<td class="formItem">95 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM SILICATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (Brownish-Red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CPC;64</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10267-0064-3</td>
<td class="formItem">15  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">10/25/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Contract Pharmacal Corp
							(968334974)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Contract Pharmacal Corp</td>
<td class="formItem"></td>
<td class="formItem">968334974</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d6192ba4-c0f7-42cf-aee1-31a6113ef190</div>
<div>Set id: 78506c63-8061-499c-a57e-bdd88f805591</div>
<div>Version: 1</div>
<div>Effective Time: 20120217</div>
</div>
</div> <div class="DistributorName">Contract Pharmacal Corp</div></p>
</body></html>
